Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Citeline Japan Awards 2024 - Enter Now!

15 July Deadline

Executive Summary

The 15 July entry deadline for the Citeline Japan Awards 2024 in Tokyo is fast approaching, so here's a reminder to take a look at the categories and criteria and be sure you get those submissions in by this date. Sponsorship opportunities and tables are also available. 

(Japanese follows English.) The Citeline Japan Awards 2024 will take place at the Palace Hotel in Tokyo on 22 October. This will be the third year for our growing Awards event in Japan, which has met with great success and much interest from the industry in this key global pharma market.

The entry deadline of 15 July is fast approaching so if you are thinking about making an entry, please take a look at the categories and criteria and submit your entry forms for the seven enterable categories by this date.

These include Best New Drug, Executive of the Year, Biotech Company of the Year, Best Contract Research Organization, Best Contract Development Manufacturing Organization, Licensing Deal of the Year, and Financing Deal of the Year.

Nominations can also be made for Pharma Company of the Year and the Lifetime Achievement Award, for which the winners are decided by a senior Citeline team.

The benefits of making an entry include exposure for your company through possible shortlisting and of course any final winners as decided by our distinguished independent judging panel would benefit from receiving the prestigious award and the recognition that comes from this.

A full guide on the criteria for each category and how to make an entry, along with all other information on the event, are available in English and Japanese at the links below. Also take this chance to book your table for the awards ceremony, which provides a great networking opportunity as well as an enjoyable evening at a wonderful venue in the heart of Tokyo.

Thank you and we look forward to seeing you there in October!

(Japanese)

日本から世界の製薬市場やバイオテック市場で活躍する企業をたたえるイベント、Citeline Japan Awards は、おかげさまで3回目を迎え、今回も2024年10月22日にパレスホテル東京で開催します。

今回の表彰カテゴリーは、

 
  • 最も優れた新薬を表彰するBest New Drug

  • 最も活躍した経営者や幹部を表彰するExecutive of the Year 

  • 目覚ましい活躍を見せたバイオテック企業を表彰するBiotech Company of the Year

  • 最も優れたCRO、そしてCDMOをそれぞれたたえるBest CRO、Best CDMO

  • 最も注目された導出、導入の契約案件を選出するLicensing Deal of the Year

  • 優れた協業、買収契約案件を選出するFinancing Deal of the Year

 

の、7つとなっています。アワードは、運営企業から独立した専門家のチームが厳正な審査を行い、受賞者を決定します。

エントリーの期限は7月15日まで。エントリーを検討されるかたは、ぜひお早めに、概要欄のリンクから、日本語版または英語版のガイドラインをご覧ください。

あわこれら7つのカテゴリーのほか、最も活躍した製薬企業をたたえるPharma Company of the Year、長いキャリアを通じて製薬業界に貢献した人物をたたえるLifetime Achievement Awardの受賞者を独自に選出いたします。

本アワードは、日本の製薬・バイオテック業界という舞台で、たがいに切磋琢磨しながら活躍するさまざまな企業の参加者たちとディナーやカクテルを楽しみながら、今後の人脈を広げていただく場にもなっております。

また、エントリーだけでなく、ぜひ会場のテーブルをご予約いただき、ご来場ください。

English-language Awards site: https://www.citeline.com/en/awards/citelinejapanawards

Japanese-language Awards site: https://www.citeline.com/ja-jp/awards/citelinejapanawards 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC150326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel